All Stories

  1. Leveraging AI for Meta‐Analysis: Evaluating LLMs in Detecting Publication Bias for Next‐Generation Evidence Synthesis
  2. Retiring the Term “Weighted Mean Difference” in Contemporary Evidence Synthesis
  3. Lifecycles of Cochrane Systematic Reviews (2003–2024): A Bibliographic Study
  4. Prospective registration was associated with a reduced risk of bias for randomized controlled trials: a meta-research study
  5. Post‐cesarean skin closure with metal staples versus subcuticular suture in obese patients: A systematic review and meta‐analysis of randomized controlled trials
  6. Tipping point analysis in network meta-analysis
  7. Prediction Performance of Earlier Studies for Later Studies in Cochrane Reviews
  8. Lack of reproducibility of trial sequential analyses: a meta-epidemiological study
  9. Confidence intervals of the relative risk and odds ratio can predict when the optimal information size in a meta-analysis is not met
  10. Trial sequential analysis involving same-year studies requires careful temporal ordering
  11. The Role of Double‐Zero‐Event Studies in Evidence Synthesis: Evaluating Robustness Using the Fragility Index
  12. Assessment of inverse publication bias in safety outcomes: an empirical analysis
  13. Robustness Assessment of Oncology Dose-Finding Trials Using the Modified Fragility Index
  14. Towards the automatic risk of bias assessment on randomized controlled trials: A comparison of RobotReviewer and humans
  15. Meta-analysis of continuous outcomes: a user’s guide for analysis and interpretation
  16. A brief note on the common (fixed)-effect meta-analysis model: comment on Veroniki and McKenzie
  17. Comparisons of various estimates of the I2 statistic for quantifying between-study heterogeneity in meta-analysis
  18. Comparisons of the mean differences and standardized mean differences for continuous outcome measures on the same scale
  19. Structural Equation Modeling Using R/SAS: A Step-by-Step Approach with Real Data Analysis
  20. Sensitivity analysis with iterative outlier detection for systematic reviews and meta‐analyses
  21. Choice of link functions for generalized linear mixed models in meta-analyses of proportions
  22. The impact of studies with no events in both arms on meta-analysis of rare events: A simulation study using generalized linear mixed model
  23. Bayesian hierarchical models incorporating study‐level covariates for multivariate meta‐analysis of diagnostic tests without a gold standard with application to COVID‐19
  24. The Active Ingredient in Reading Comprehension Strategy Intervention for Struggling Readers: A Bayesian Network Meta-analysis
  25. Methods for deriving risk difference (absolute risk reduction) from a meta-analysis
  26. The normality assumption on between-study random effects was questionable in a considerable number of Cochrane meta-analyses
  27. Assessing the robustness of results from clinical trials and meta-analyses with the fragility index
  28. THE EFFECT DIRECTION SHOULD BE TAKEN INTO ACCOUNT WHEN ASSESSING SMALL-STUDY EFFECTS
  29. Meta-analysis methods for risk difference: A comparison of different models
  30. Data extraction error in pharmaceutical versus non-pharmaceutical interventions for evidence synthesis: Study protocol for a crossover trial
  31. Limits in the search date for rapid reviews of diagnostic test accuracy studies
  32. A Retrospective Analysis of Biological Complications of Dental Implants
  33. A Bayesian model for combining standardized mean differences and odds ratios in the same meta-analysis
  34. Synthesizing evidence from the earliest studies to support decision‐making: To what extent could the evidence be reliable?
  35. Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package
  36. Accounting for publication bias using a bivariate trim and fill meta‐analysis procedure
  37. Meta-analysis methods for risk difference: a comparison of different models
  38. Empirical comparisons of meta-analysis methods for diagnostic studies: a meta-epidemiological study
  39. Comment on a review of methods to assess publication and other reporting biases in meta‐analysis
  40. Empirical comparisons of heterogeneity magnitudes of the risk difference, relative risk, and odds ratio
  41. The Odds Ratio is “portable” across baseline risk but not the Relative Risk: Time to do away with the log link in binomial regression
  42. Bridging randomized controlled trials and single-arm trials using commensurate priors in arm-based network meta-analysis
  43. A penalization approach to random‐effects meta‐analysis
  44. Methodological quality for systematic reviews of adverse events with surgical interventions: a cross-sectional survey
  45. Predictive P-score for treatment ranking in Bayesian network meta-analysis
  46. Estimating Partial Standardized Mean Differences from Regression Models
  47. Rapid evidence synthesis approach for limits on the search date: How rapid could it be?
  48. Empirical Comparisons of 12 Meta-analysis Methods for Synthesizing Proportions of Binary Outcomes
  49. The impact of studies with no events in both arms on meta-analysis of rare events: a simulation study using generalized linear mixed model
  50. Synthesis of evidence from zero‐events studies: A comparison of one‐stage framework methods
  51. Good Statistical Practices for Contemporary Meta-Analysis: Examples Based on a Systematic Review on COVID-19 in Pregnancy
  52. Bayesian meta‐analysis using SAS PROC BGLIMM
  53. A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies
  54. Utilization of the evidence from studies with no events in meta-analyses of adverse events: an empirical investigation
  55. Methodological assessment of systematic reviews and meta‐analyses on COVID ‐19: A meta‐epidemiological study
  56. Double-zero-event studies matter: A re-evaluation of physical distancing, face masks, and eye protection for preventing person-to-person transmission of COVID-19 and its policy impact
  57. Bayesian Methods for Meta-Analyses of Binary Outcomes: Implementations, Examples, and Impact of Priors
  58. The influence of insertion torque values on the failure and complication rates of dental implants: A systematic review and meta‐analysis
  59. Many meta-analyses of rare events in the Cochrane Database of Systematic Reviews were underpowered
  60. Empirical assessment of prediction intervals in Cochrane meta‐analyses
  61. Prior Choices of Between-Study Heterogeneity in Contemporary Bayesian Network Meta-analyses: an Empirical Study
  62. Systematic identification of risk factors and drug repurposing options for Alzheimer's disease
  63. BayesSenMC: an R package for Bayesian Sensitivity Analysis of Misclassification
  64. Evidence inconsistency degrees of freedom in Bayesian network meta-analysis
  65. Protocols for meta-analysis of intervention safety seldom specified methods to deal with rare events
  66. PALM: Patient-centered Treatment Ranking via Large-scale Multivariate Network Meta-analysis
  67. Evaluation of various estimators for standardized mean difference in meta‐analysis
  68. Questionable utility of the relative risk in clinical research: a call for change to practice
  69. A Bayesian Approach for Determining the Relationship Between Various Elongate Mineral Particles (EMPs) Definitions
  70. Fragility index of network meta-analysis with application to smoking cessation data
  71. Peto odds ratios demonstrate no advantage over classic odds ratios in meta-analysis of binary rare outcomes
  72. Meta-analysis of Proportions Using Generalized Linear Mixed Models
  73. Double-zero-event studies matter: a re-evaluation of physical distancing, face masks, and eye protection for preventing person-to-person transmission of COVID-19 and its policy impact
  74. A variance shrinkage method improves arm-based Bayesian network meta-analysis
  75. Accounting for small-study effects using a bivariate trim and fill meta-analysis procedure
  76. Arcsine‐based transformations for meta‐analysis of proportions: Pros, cons, and alternatives
  77. Systematic identification of modifiable risk factors and drug repurposing options for Alzheimer’s disease: Mendelian randomization analyses
  78. Exclusion of studies with no events in both arms in meta-analysis impacted the conclusions
  79. Effects of treatment classifications in network meta-analysis
  80. A Bayesian approach to assessing small‐study effects in meta‐analysis of a binary outcome with controlled false positive rate
  81. Laplace approximation, penalized quasi-likelihood, and adaptive Gauss–Hermite quadrature for generalized linear mixed models: towards meta-analysis of binary outcome with sparse data
  82. Factors that impact fragility index and their visualizations
  83. The impact of covariance priors on arm‐based Bayesian network meta‐analyses with binary outcomes
  84. Hybrid test for publication bias in meta-analysis
  85. P value–driven methods were underpowered to detect publication bias: analysis of Cochrane review meta-analyses
  86. On evidence cycles in network meta-analysis
  87. Use of Prediction Intervals in Network Meta-analysis
  88. The magnitude of small-study effects in the Cochrane Database of Systematic Reviews: an empirical study of nearly 30 000 meta-analyses
  89. Comparison of four heterogeneity measures for meta‐analysis
  90. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses
  91. Real-world Performance of Meta-analysis Methods for Double-Zero-Event Studies with Dichotomous Outcomes Using the Cochrane Database of Systematic Reviews
  92. Graphical augmentations to sample-size-based funnel plot in meta-analysis
  93. Borrowing of strength from indirect evidence in 40 network meta-analyses
  94. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation
  95. Performance of Between-study Heterogeneity Measures in the Cochrane Library
  96. Re: Incidence and Risk Factors for Prediabetes and Diabetes Mellitus Among HIV-infected Adults on Antiretroviral Therapy: A Systematic Review and Meta-analysis
  97. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model
  98. Bias caused by sampling error in meta-analysis with small sample sizes
  99. Quantifying and presenting overall evidence in network meta-analysis
  100. Empirical Comparison of Publication Bias Tests in Meta-Analysis
  101. The effect of publication bias magnitude and direction on the certainty in evidence
  102. Bayesian multivariate meta-analysis of multiple factors
  103. Quantifying publication bias in meta-analysis
  104. Rejoinder to “quantifying publication bias in meta-analysis”
  105. Cross channel effects of search engine advertising on brick & mortar retail sales: Meta analysis of large scale field experiments on Google.com
  106. Performing Arm-Based Network Meta-Analysis in R with the pcnetmeta Package
  107. An adaptive two-sample test for high-dimensional means
  108. Sensitivity to Excluding Treatments in Network Meta-analysis
  109. Alternative measures of between-study heterogeneity in meta-analysis: Reducing the impact of outlying studies